Thursday, September 23, 2021
Home National DCGI grants approval to Sanofi-GSK to conduct Phase III clinical trial of...

DCGI grants approval to Sanofi-GSK to conduct Phase III clinical trial of COVID-19 vaccine

The Drugs Controller General of India (DGCI) has approved Sanofi and GlaxoSmithKline to conduct Phase III studies to assess the safety, efficacy and immunogenicity of their anti-COVID-19 vaccines in India. The double-blind phase-III study will involve over 35,000 volunteers aged 18 years. The main objective of the test is to prevent COVID-19 infection as well as reduce severe disease symptoms. The initial study will examine the efficacy of a vaccine formulation targeting the virus strain (D614), while the second phase will evaluate a second formulation targeting the beta variant (B1351). The Phase II trial involved 722 adults aged between 18 and 95.

Read more: Zee News | Free Press Journal | India Today

Report Post

Swapnil Surwade
Conter Writer - News, Research Content, Web Content Writing, Content writer @Headline Hindi @Headline Network

TRENDING NEWS

LATEST NEWS